Oppenheimer is out with its report today on Amgen AMGN, maintaining Outperform.
In a note to clients, Oppenheimer writes, "While the company is facing a number of regulatory and competitive headwinds, we believe revenues from Amgen's core franchises are nearing stabilization. We believe Amgen's near-term growth will be driven by sales of denosumab, a novel treatment for bone loss. Additionally, we believe denosumab's market opportunity in osteoporosis and oncology indications such as SRE prevention and bone mets prevention are undervalued."
Oppenheimer maintains a $66 PT on AMGN.
Shares of AMGN closed Monday at $57.88, up 1.47% from Friday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in